January 05, 2011
Actemra gains indication for inhibition and improvement of RA
The study also showed that patients who received Actemra 4mg/kg or 8mg/kg plus MTX showed significant improvement in physical function, compared with patients who received MTX plus placebo at week 52 (63% and 60%, respectively, compared to 53%). More patients treated with Actemra also achieved major clinical response (7% and 4%, respectively), defined as achieving an American College of Rheumatology Criteria (ACR) 70 response for a continuous 24-week period, compared to MTX plus placebo (1%).
Actemra is already indicated to treat moderately to severe active RA in adult patients after an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. It can be used as monotherapy or in combination with MTX or other disease modifying anti-rheumatic drugs (DMARDS).
For more information call (800) 228-3672 or visit www.actemra.com.